Compare API & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | API | TTRX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.8M | 298.8M |
| IPO Year | 2020 | 2025 |
| Metric | API | TTRX |
|---|---|---|
| Price | $4.44 | $10.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.90 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 128.6K | 90.8K |
| Earning Date | 11-18-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.12 | N/A |
| Revenue Next Year | $16.06 | $900.00 |
| P/E Ratio | $92.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $2.57 |
| 52 Week High | $5.50 | $16.45 |
| Indicator | API | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.63 | 39.39 |
| Support Level | $4.32 | $9.02 |
| Resistance Level | $4.60 | $10.72 |
| Average True Range (ATR) | 0.16 | 0.85 |
| MACD | 0.03 | -0.23 |
| Stochastic Oscillator | 87.98 | 9.94 |
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.